Pharmaceutical
Biopharmaceutical
Biotechnology
ImmunoGen
$1.939876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
$0.00 (0.00%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ImmunoGen and other stocks, options, ETFs, and crypto commission-free!
About
ImmunoGen, Inc. Common Stock, also called ImmunoGen, is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Read More Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.
Employees
296
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
288.39M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.87M
High Today
$1.97
Low Today
$1.83
Open Price
$1.91
Volume
1.57M
52 Week High
$12.31
52 Week Low
$1.83
Collections
Pharmaceutical
Biopharmaceutical
Biotechnology
Therapy
Cancer Prevention
Technology
Health
US
News
Seeking AlphaMay 17
ImmunoGen: Assessing The Possibility Of A Turnaround
There is an aplenty of cash to fund its highly interesting pipeline. Other molecules have an excellent chance of delivering good results. Altogether, ImmunoGen is an excellent turnaround prospect to reward investors. With better endpoint guidance for positive results, I believe that the new investigation will bear excellent outcomes. After all, ImmunoGen now realized that mirvetuximab works best for high folate-alpha expression. ImmunoGen shares recently tumbled due to a negative regulatory binary. Amid t...
MarketWatchMay 16
ImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losers
Shares of ImmunoGen Inc. led biotech’s losers on Wednesday, falling 38% in intraday trade after the company disclosed that the U.S. Food and Drug Administration had recommended it run a second Phase 3 trial of an ovarian cancer drug. A first Phase 3 trial of the biotech’s IMGN, +0.52% investigational drug, called mirvetuximab soravtansine, failed to show that patients on the therapy had better progression-free survival or overall survival than those on chemotherapy. Despite the disappointment, the company ...
Yahoo FinanceMay 15
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
WALTHAM, Mass.--(BUSINESS WIRE)-- Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Scroll to continue with content Ad Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive Patients ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announ...
Price Paid on Robinhood
35% Lower
Right Now
52 Week Low
$1.83
Average Price Paid
$2.99
52 Week High
$12.31
Earnings
-$0.37
-$0.28
-$0.19
-$0.10
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 26, Pre-Market